Myotropic neuropeptides were isolated from the retrocerebral complex of the stick insect, Carausius morosus, by using three HPLC steps. Bioactivity during purification was measured by heterologous bioassays monitoring the contractions of the hyperneural muscle and hindgut of the American cockroach. Additionally, fractions not active in these bioassays were tested in a homologous bioassay evoking contractions of the hindgut of C. morosus. Peptide sequence analysis and mass spectrometry yielded the following structures: Pro-Phe-Cys-Asn-Ala-Phe-Thr-Gly-Cys-NH2 (CCAP), pGlu-Thr-Phe-Gln-Tyr-Ser-His-Gly-Trp-Thr-Asn-NH2 (His7-corazonin) and Asp-Glu-Gly-Gly-Thr-Gln-Tyr-Thr-Pro-Arg-Leu-NH2 (Cam-PK-1). These neuropeptides are the first myotropins isolated from C. morosus. The most bioactive compound in the homologous bioassay, the C. morosus-hindgut assay, was CCAP., Reinhard Predel, Roland Kellner, Gerd Gäde, and Lit
Ghrelin is a new endogenous ligand for the growth hormone secretagogue receptor. It activates the release of growth hormone from the pituitary and it also participates in the regulation of energy homeostasis. The aim of the study was to characterize changes in serum ghrelin levels in obese subjects and their relationship to the serum levels of leptin and soluble leptin receptor. Eight obese patients (6 women and 2 men) with body mass index (BMI) 40.313.4 kg.m-2 and eight healthy controls (5 women and 3 men) with BMI 22.7±1.3 kg.m-2 were examined. The ghrelin serum levels (165.0±58.1 vs. 343.37±81.96; p<0.001) and soluble leptin receptor serum levels (7.25±3.44 vs. 21.80±4.99; p<0.0001) were significantly lower in obese patients. The leptin serum levels (23.45±12.90 vs. 6.41±2.96; p<0.005) were significantly higher compared to the lean subject group. In both measured groups the levels of serum leptin significantly positively correlated with BMI. We proved a significantly lower serum ghrelin levels in the group of obese patients in comparison with the control group., M. Rosická, M. Kršek, M. Matoulek, Z. Jarkovská, J. Marek, V. Justová, Z. Lacinová., and Obsahuje bibliografii
Leptin, a cytokine-like hormone secreted by adipocytes, is known to regulate food intake but has also emerged as a significant factor in the regulation of bone mass. In humans, states of energy deprivation with low serum leptin have been associated with low bone mass. In mice, leptin deficiency led to increased trabecular bone mass with overall decrease in cortical bone. Leptin regulates bone metabolism indirectly in the hypothalamus thereby activating the sympathetic nervous system (SNS). In addition to the SNS, leptin also interacts with various hypothalamic neuropeptides, such as cocaine- and amphetamine-regulated transcript, neuropeptide Y and/or neuromedin U, which might modulate the effects of leptin on bone. In osteoblasts sympathetic signaling is further gated by the transcriptional factors called molecular clock. As a result, bone loss is accelerated showing that the central effect of leptin seems to be antiosteogenic. Additionally, leptin has a direct anabolic effect within the bone driving the differentiation of bone marrow stem cells into the osteoblastic cell lineage. Besides the interaction between the central and peripheral pathways, the overall effect of leptin on bone might be bimodal depending on leptin serum concentrations. Regulatory pathways triggering osteoblast activity might open new possibilities for anabolic treatment of osteoporosis., V. Cirmanová, M. Bayer, L. Stárka, K. Zajíčková., and Obsahuje bibliografii a bibliografické odkazy